Integra LifeSciences receives ‘hold’ rating — 4 notes

Zacks upgraded Integra LifeSciences, a health technology company, from a “sell” rating to a “hold” rating, according to Financial Wisdom.

Advertisement

Here are four notes:

 

1. The company’s second quarter results surpassed the Zacks Consensus Estimate.

 

2. Integra LifeSciences has a 50-day moving average of $62.24 and a 200-day moving average of $59.00.

 

3. The company has a 52-week low of $42.09 and a 52-week high of $68.46.

 

4. Integra LifeSciences has a market cap of $2.05 billion and a PE ratio of 51.03.

 

More articles on devices:
Nextremity Solutions’ Arcus Staple System receives FDA approval: 4 quick facts
Blue Belt Technologies’ Navio system supports Smith & Nephew’s ZUK uni knee: 5 notes
Orchid acquires Alhenia coated orthopedic implant company: 4 key notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.